Zealand Pharma grants exclusive license for type 1 diabetes peptide
The Copenhagen-listed peptide developer has handed a partner exclusive rights to a candidate aimed at type 1 diabetes.
TR
By Tom Reyes · Markets Editor
Sep 18 05:14 ETSource: finance.yahoo.com
The wire
- 01Zealand Pharma (CPSE:ZEAL) has granted an exclusive license covering a peptide candidate for type 1 diabetes.
- 02Zealand is one of the few pure-play peptide developers outside the incretin majors, and out-licensing shapes which of its programs advance and who funds them.
- 03Financial terms, the partner and the development timeline were not detailed in the report.
From the source
Read at finance.yahoo.comZealand Pharma (CPSE:ZEAL) Grants Exclusive Type 1 Diabetes Peptide License